LabCorp Extends Orchid Tender Offer - Analyst Blog
16 Noviembre 2011 - 11:09AM
Zacks
Laboratory Corporation of America Holdings (LH)
has once again extended the tender offer for Orchid
Cellmark (ORCH) until November 30, 2011. The company had
earlier extended the tender offer to November 14.
In May 2011, the company received a request from the Federal
Trade Commission (FTC) for some additional information related to
the transaction. LabCorp is cooperating with the FTC on this issue.
To date, about 86.8% of the outstanding shares of Orchid have been
tendered.
LabCorp had decided in April 2011 to acquire Orchid Cellmark for
$2.80 per share, coming to a total consideration of $85.4 million,
all in cash. After taking into account Orchid Cellmark’s cash
balance, LabCorp’s net payable comes to $65.6 million. Orchid
Cellmark provides DNA testing services targeted towards forensic
and family relationship applications on a global basis.
This deal would enable LabCorp to command a leading position in
identity testing in the US and also establish its presence in this
field in the UK. The company derives 64% of its revenues from core
routine tests. It also provides specialty testing services in the
areas of allergy, clinical trials, diagnostic genetics, identity,
forensics, infectious disease, oncology and occupational testing,
which accounted for the remaining 40%.
LabCorp has of late put more and more emphasis on specialized
testing. Towards this end, the company undertook a number of
acquisitions notable among which are Monogram Bioscience (August
2009) and Genzyme Genetics (December 2010). LabCorp has set a
target of garnering 45% of its revenues from the specialty business
in the next 3-5 years.
During the most recent quarter, esoteric volume increased 7%
over the prior year. The company has also expanded its portfolio of
tests in the field of women’s health and personalized medicine.
LabCorp continues to focus on strategic initiatives to drive
growth and profitability. However, the tough competitive landscape
is of primary concern, and the leading diagnostic players are
striving hard for a greater share of the high-margined, specialized
testing business. In such a quest, Quest
Diagnostics (DGX) has acquired neurological diagnostic
test specialist Athena Diagnostics and Celera Corp.
We are currently Neutral on LabCorp, which also corresponds with
the Zacks #3 Rank (Hold) in the short term. For Quest Diagnostics,
we have a Neutral recommendation.
QUEST DIAGNOSTC (DGX): Free Stock Analysis Report
LABORATORY CP (LH): Free Stock Analysis Report
ORCHID CELLMARK (ORCH): Free Stock Analysis Report
Zacks Investment Research
Orchid Cellmark (NASDAQ:ORCH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Orchid Cellmark (NASDAQ:ORCH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024